Abstract Body

Background: A betulinic acid-based compound, bevirimat (BVM), the first-in-class HIV-1 maturation inhibitor, acts by blocking a late step in proteasemediated Gag processing: the cleavage of the capsid-spacer peptide 1 (CA-SP1) intermediate to mature CA. BVM was shown in multiple clinical trials to be safe and effective in reducing viral loads in HIV-1-infected patients. However, single-amino-acid polymorphisms in the SP1 region of Gag resulted in variable response in BVM-treated patients, leading to the discontinuation of BVM’s clinical development. Methodology: We carried out an extensive medicinal chemistry campaign to develop BVM derivatives that demonstrate not only increased potency against consensus clade B strains of HIV-1 but also that are active against isolates with polymorphisms in SP1 and primary, non-clade B isolates. Compound activity was tested in assays that measure CA-SP1 processing by radioimmunoprecipitation, single-cycle infectivity, cell-cell transmission, and virus replication kinetics. Long-term selection experiments were performed to identify mutations that confer resistance to these novel compounds. Compound binding to Gag was tested directly by using a tritium-labeled derivative. The effects of the compounds on virion morphology were examined at high resolution by cryo-electron tomography Results: We identified a set of BVM derivatives that are not only more potent than BVM against WT HIV-1 but also show robust antiviral activity against SP1 polymorphic strains and clade C isolates. These second-generation inhibitors are structurally similar to BVM with C28 heteroatom modifications. The best of these analogs displayed ~3-log improved potency against polymorphic HIV-1 relative to BVM. Selection experiments identified a panel of resistant mutants that contain substitutions in Gag. The resistance mutations were analyzed for their effect on viral assembly, viral fitness, CA-SP1 processing, compound binding, and particle morphology. Cryo-electron tomography analysis demonstrated that HIV-1 maturation inhibitors act not only by blocking CA-SP1 processing but also by stabilizing the immature Gag lattice. Conclusions: This study identifies a panel of C28 BVM derivatives that display marked improvements relative to BVM in their potency and breadth of activity. Biochemical, virological, and structural analyses performed with these compounds provide novel insights into the target and mechanism of action of HIV-1 maturation inhibitors. The results of this study provide novel insights into the structure of the maturation inhibitor-binding site and the role of SP1 in virus assembly and maturation. Finally, these findings suggest that clinical development of HIV-1 maturation inhibitors should resume.